Clinical Trial Update: Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC] [Phase 2]

View source ↗

Summary

Phase 2 trial of weekly or every-3-week docetaxel plus prednisone in hormone-refractory prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Docetaxel (Taxotere) (docetaxel)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Sanofi | Conditions: Prostatic Neoplasms | Phase 2 | Status: COMPLETED